Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells
Colby R. Maldini, Angelica Messana, Paula B. Bendet, Adam J. Camblin, Faith Musenge, Moriah White, Joseph J. Rocha, Lindsey Coholan, Cisem Karaca, Frederick W. B. Li, Bo Yan, Vladimir Vrbanac, Emily Marte, Daniel T. Claiborne, Christian L. Boutwell, Todd M. Allen
Abstract
19CAR-T cell-driven B cell aplasia. Thus, we demonstrate that genome engineering enables immunosuppressant treatment to improve the therapeutic potential of universal donor-derived CAR-T cells.
Topics & Concepts
ImmunologyMedicineCAR-T cell therapy researchImmune Cell Function and InteractionSilicon Carbide Semiconductor Technologies